ArriVent Biopharma Q3 net loss widens 15% to $40.31 million
AVBP•ArriVent BioPharma’s third-quarter net loss widened 15% year over year to $40.31 million, while collaboration revenue reached $5 million. Cash and investments totaled $393.2 million at September 30, 2026, and the company expects them to fund operations through mid-2028.
1. Quarterly results and pipeline
ArriVent BioPharma’s third-quarter net loss widened 15% year over year to $40.31 million, while collaboration revenue reached $5 million. Research and development expenses rose 21% to $38.9 million, and general and administrative expenses climbed 54% to $9.48 million. The company reported $393.2 million in cash and investments at September 30, 2026, which it expects to fund operations through mid-2028. Firmonertinib’s Phase 3 FURVENT trial missed its primary endpoint; ArriVent plans an update following its data review in the first quarter of 2027. Preliminary Phase 1 ARR-217 data showed a 44.8% response rate among evaluable colorectal cancer patients receiving 6 mg/kg, including unconfirmed responses.
